Abstract 218P
Background
Adjuvant chemotherapy improved disease-free survival (DFS) among MIUC patients (pts). CheckMate 274 study demonstrated adjuvant immunotherapy improved DFS in MIUC pts. However, few studies explored the efficacy of adjuvant chemotherapy plus immunotherapy in MIUC pts. Our real-world study aimed to evaluate the effectiveness of adjuvant chemoimmunotherapy versus chemotherapy in high-risk MIUC pts.
Methods
Clinical data of high-risk MIUC pts between October 2016 and March 2023 were retrospectively collected from Sun Yat-sen University Cancer Center. After radical surgery, pT3/4 and pN+ MIUC pts without prior neoadjuvant therapy received adjuvant tislelizumab combined with GC (T+GC) or GC. In T+GC group, pts firstly received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles, then received tislelizumab 200 mg every 3 weeks for 2-17 cycles. In GC group, pts received cisplatin 70 mg/m2 D2, and gemcitabine 1000 mg/m2 D1 and D8 every 3 weeks for 2-6 cycles. The primary outcome was DFS, and secondary outcomes were OS and safety.
Results
The median follow-up was 17.7(2.1-38.3) months, totally 117 MIUC pts were analyzed, with a median age of 64 (34-85) years. 75.2% were male, 46.2% were UTUC, 20.5% were variant histology; pT3=58.9%, pT4=17.1%; pN+=52.1%. In T+GC group (n=68), the mean number of tislelizumab cycles was 4 and GC cycles was 2.7. In GC group (n=49), the mean number of GC cycles was 2.9. The T+GC group (n=68) had a significantly longer DFS compared with the GC group (n=49) (median DFS (95% CI): 19.1 (6.0-32.5) vs 8.4 (1.0-39.4) months, HR=0.172, P<0.001). While lymphovascular invasion pts had a lower probability of DFS (HR=22.1 (2.8-173.5), P=0.003). The OS was longer in the T+GC group (n=68) (median OS (95% CI): 20.1(6.0-32.5) vs 12.2(1.5-39.4) months, P=0.186). Longer follow-up was required to determine the OS benefits in T+GC group. Grade 1-2 immune related adverse events including pruritus (n=10), ALT/AST increased (n=8), hyperthyroidism (n=5) and hyperglycaemia (n=3).
Conclusions
Our data demonstrated effectiveness of tislelizumab combined with GC as adjuvant therapy for pT3/4 and pN+ MIUC pts in real world.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract